The Center For The Improvement Of Human Functioning International
A Non-profit Medical, Research and Educational Organization
3100 North Hillside Avenue, Wichita, KS 67219 USA
Phone: 316-682-3100; Fax: 316-682-5054

---

Intravenous Ascorbic Acid:
Protocol for its Application and Use

By Hugh D. Riordan, Ronald E. Hunninghake, Neil H. Riordan, James A. Jackson, Xiao LongMeng, Paul Taylor, et al, from Puerto Rico Health Sciences Journal (2003) 22:3, 287-290

Introduction
High dose intravenouse (IV) ascorbic acid (AA) has been used as therapy for infectious disease from bacterial and viral origin and adjuvant therapy for cancer. In this publication we describe a clinical protocol that has been developed over the past twenty years utilizing high dose IV AA as therapy for cancer. This includes principles of treatment, rationale, baseline workup, infusion protocol, precautions and side effects.

High dose intravenouse ascorbic acid (IAA) has been used as a therapy for bacterial infection, viral infection, and as adjuvant therapy for cancer (1-7). The treatment rationale for the use or IAA in treatment of cancer has been described in detail elsewhere (7-9). In general cancer patients have depressed circulatory, cellular and tissue ascorbate levels and reserves. Ascorbate administered in pharmacological doses enhances various parameters associated with better prognosis (7,8). There is also evidence that physiologically attainable concentrations by intravenouse administration are selectively toxic to cancer cells (3-7,10); contrary to the limited levels of asoccorbate that can be reached by oral intakes. Moreover, there is evidence of synergism between the conventional methods for cancer treatment (surgery, ratiation and chemotherapy) when utilized with ascorbate (11-13).